Azurette
NDC Package 53002-1600-3

11-digit billing NDC: 53002160003

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Azurette is ® (desogestrel/ethinyl estradiol and ethinyl estradiol tablets USP) is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.Oral contraceptives are highly effective. Marketed by Rpk Pharmaceuticals, Inc., this product is identified by NDC 53002-1600 and is authorized under FDA application ANDA075863.

Identification & Billing

NDC Package Code
53002-1600-3
Package Description
3 BLISTER PACK in 1 PACKAGE / 1 KIT in 1 BLISTER PACK
Product Code
11-Digit Billing Format
53002160003
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Azurette
Dosage Form
-
Usage Information
Azurette® (desogestrel/ethinyl estradiol and ethinyl estradiol tablets USP) is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.Oral contraceptives are highly effective. Table II lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of these methods can result in lower failure rates.TABLE II: Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year, United States. % of Women Experiencing an Unintended Pregnancy within the First Year of Use% of Women Continuing Use atOne Year*(4)Method (1)Typical Use†(2)Perfect Use‡ (3)Chance§ 8585Spermicides¶26640Periodic Abstinence2563 Calendar9 Ovulation Method3 Sympto-Thermal# 2 Post-Ovulation1Withdrawal194CapÞ  Parous Women402642 Nulliparous Women20956Sponge Parous Women402042 Nulliparous Women20956DiaphragmÞ 20656Condomß  Female (Reality)21556 Male14361Pill571 Progestin Only0.5 Combined0.1IUD Progesterone T21.581 Copper T 380A0.80.678 LNg 200.10.181Depo-Provera0.30.370Norplant and Norplant-20.050.0588Female Sterilization0.50.5100Male Sterilization0.150.10100Adapted from Hatcher et al., 1998, ref #1.

Regulatory & Marketing

Labeler Name
Rpk Pharmaceuticals, Inc.
FDA Application #
ANDA075863
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
11-14-2016
Listing Expiration
12-31-2022
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (53002-1600). Click a package code to view its specific billing and regulatory data.

1 BLISTER PACK in 1 PACKAGE / 1 KIT in 1 BLISTER PACK
6 BLISTER PACK in 1 PACKAGE / 1 KIT in 1 BLISTER PACK

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 53002-1600-3 identifies a specific commercial package of 3 blister pack in 1 package / 1 kit in 1 blister pack of Azurette, labeled by Rpk Pharmaceuticals, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Rpk Pharmaceuticals, Inc. on November 14, 2016. The current certification is valid through December 31, 2022.

How is this Rpk Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 53002160003. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
53002-1600-3
11-Digit CMS (5-4-2)
53002-1600-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.